2 completed, 2 unknown, 1 not yet recruiting, 1 withdrawn. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow CHOP: new trials by email Literature Review of CHOP trials Research Report on CHOP
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| New Genotype-guided Treatment in Newly Diagnosed PTCL Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2026-07-01 | 2026-07-16 |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients Vincristine Sulfate Liposome, CHOP, R-CHOP - Hematologic Diseases | Phase 1 | Unknown | Acrotech Biopharma Inc. | 56 | 2020-08-15 | 2020-04-16 |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Belinostat, CHOP - Peripheral T-cell Lymphoma | Phase 1 | Completed | Acrotech Biopharma Inc. | 23 | 2013-05-01 | 2020-01-03 |
| Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma darinaparsin, CHOP - Lymphoma | Phase 1 | Withdrawn | Alaunos Therapeutics | 2010-06-01 | 2012-07-19 | |
| CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas CHOP, Alemtuzumab, Plasma Samples - Non-Hodgkin's Lymphoma | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 24 | 2004-03-01 | 2017-01-20 |
Lymphoma, T-Cell, Peripheral (2) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Acrotech Biopharma Inc. (2) · Alaunos Therapeutics (1) · Fudan University (1) · Ohio State University Comprehensive Cancer Center (1) · Ruijin Hospital (1)
United States (2) · China (1)
Jonathan J. Lewis, MD, PhD (1) · Junning Cao (1) · Mi Rim Choi, MD (1) · Pierluigi Porcu, MD (1) · Wasim Khan, MD (1)